Abstracts from XVII Mexican Congress of Hepatology
Más datosThis study aimed to determine the prevalence of liver fibrosis through non-invasive methods in patients with metabolic disorders.
Materials and MethodsObservational, cross-sectional, and retrospective analytical study. Laboratory results and images of patients diagnosed with metabolic alterations in the CMN 20 de Noviembre will be collected.
ResultsAmong the results obtained, we found that the prevalence of fibrosis was 18.1%, and hepatic steatosis was 59.8%.
DiscussionALT, C-peptide, and insulin levels were significantly higher in the group with fibrosis. When the variables were dichotomized, an OR of 2.91 (95% CI 1.099 – 7.73) was found for ALT >38.5; Insulin > 17.75, the OR was 3.199 (95% CI 1.20 – 8.5); and for C-peptide > 945 OR 4.049 (95% CI 1.42 – 11.51). The albumin level was significantly lower in this group p = 0.041, with an OR 0.29 (95% CI 0.104 – 0.815), so a value greater than 4.35 represents a protective factor. The NALFD score and FIB4 showed a weak positive correlation with the measurements made with the Fibroscan®.
ConclusionsThe determination of liver fibrosis did not correlate through the different non-invasive methods, so it would be best to establish non-invasive liver-specific markers in patients with metabolic disorders and steatohepatitis for the diagnosis of liver fibrosis; since the necessary and accurate diagnostic tools that meet the criteria of efficacy, accuracy, and reliability are not available.
FundingThe resources used in this study were from the hospital without any additional financing
Declaration of interestThe authors declare no potential conflicts of interest.